JPMorgan's creative approach helped Casino Guichard-Perrachon to raise the finance it needed to stave off a liquidity crunch, while also keeping existing bondholders happy.
Latest articles from Issuers

Austria shows good debt improves with maturity
March 2, 2020Austria has defied market expectations with a century bond issuance that garnered significant investor interest, at rock-bottom rates.

Boston Scientific makes splash on European debut
February 3, 2020Following several acquisitions of European companies, US-based Boston Scientific has issued its first batch of euro-denominated bonds.

Marfrig shakes-up sustainable finance with beef bond
January 2, 2020With demand for climate-friendly finance growing exponentially, Marfrig has entered the fray with a bond to support sustainable beef production.

Caixa opens Spanish market for SDG bonds
November 1, 2019CaixaBank's charitable roots explain its success in launching the first Spanish bond linked to the UN Sustainable Development Goals.

Network International £1bn IPO sets pulses racing
July 2, 2019Dubai-based Network International piqued investor interest in April when it floated on the London Stock Exchange in Europe's biggest IPO listing. David Wigan reports.

Recovering UniCredit makes return to form with bond bonanza
May 1, 2019UniCredit's restructuring programme has paid off, enabling the Italian bank to return to the market with a handful of regulatory capital deals.

Belgium's bond double-dip pays off
April 1, 2019While Belgium's economy is thriving, supporting its complex regional make-up has driven up debt levels. To this end, the country's debt agency recently launched two long bonds.

Acquisition hungry Takeaway.com cooks up a debt and equity storm
March 1, 2019Netherlands-based Takeaway.com has been on an acquisition spree around Europe. The Banker looks at its use of the debt and equity markets to finance this activity.

IPO proves the right medicine for MedinCell
January 2, 2019When France's MedinCell needed funding to progress with the launch of a newly developed drug, it decided the time was right for a long-planned IPO. David Wigan reports.